Skip to main content
. Author manuscript; available in PMC: 2022 Feb 1.
Published in final edited form as: Ann Surg Oncol. 2020 Aug 19;28(2):968–974. doi: 10.1245/s10434-020-08863-2

Fig. 2. Axillary management by receptor subtype.

Fig. 2.

HER2 human epidermal growth factor receptor 2, TNBC triple negative breast cancer, ER estrogen receptor, SNLB sentinel lymph node biopsy, ALND axillary lymph node dissection